Obesity / metabolic
Incretin and next-wave oral/combination approaches competing on efficacy, tolerability, and access.
Lenses
EarlierApproval →
NVOPh3cash ok
2026-10-10 (-7d)Company-guided
CagriSema · NCT05567726 · Phase 3 combo data
LLYPh3cash ok
2026-11-01 (15d)Company-guided
Retatrutide triple agonist · NCT05929066 · Phase 3 obesity readout
AMGNPh3cash ok
2027-01-15 (90d)Company-guided
MariTide · NCT06164834 · Phase 3 obesity update
VKTXPh2cash ok
2026-09-15 (-32d)Company-guided
VK2735 dual agonist · NCT06068946 · Phase 3 start / design
GPCRPh2cash ok
2026-12-20 (64d)Estimated
Oral GLP-1 · NCT06085729 · Phase 2b readout